The abstract is read at the publisher; the summary is JClub's.
AZD6912, a GalNAc-conjugated siRNA silencing hepatic complement factor B, achieved >80% suppression of hepatic CFB mRNA and >95% inhibition of complement activity in non-human primates.
- Why it matters: Complement dysregulation can fuel inflammation and tissue injury in autoimmune and inflammatory diseases, creating a need for targeted therapies that modulate complement activity.
- What they did: The study developed AZD6912 and tested hepatic CFB knockdown in hepatocyte models, then evaluated in mice and non-human primates using hepatic-targeted siRNA and measurements of liver Cfb mRNA, serum CFB protein, and complement activity.
- The result: Hepatic CFB silencing reduced local complement production and attenuated joint inflammation with therapeutic benefit in the CAIA model, while non-human primate data showed sustained serum CFB reductions and strong complement inhibition.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.